A retrospective study. To evaluate the clinical and radiological outcomes of ankylosing spinal disorder (ASD) patients with spinal fractures treated by minimally invasive stabilization (MISt) using percutaneous pedicle screws (PPSs). ASDs, such as ankylosing spondylitis (AS) and diffuse idiopathic skeletal hyperostosis (DISH), increase susceptibility to spinal fractures because of extremely decreased spinal flexibility. Such fractures tend to be unstable and, consequently, should be treated with multiple-segmental internal fixation. However, conventional internal fixation procedures can severely damage the soft tissue, resulting in severe hemorrhage. Therefore, MISt is the preferred approach to treat spinal fractures in ASD patients. Nine ASD patients (four males and five females; three AS and six DISH patients) with spinal fractures who were treated by MISt using PPSs, were reviewed from April 2009 to August 2016. One patient died of aspiration pneumonia during follow-up (FU), and the remaining eight patients underwent clinical and radiological evaluation. The mean age at surgery was 79.6 years (range, 68-95 years). The mean duration of postoperative FU was 14.2 months (range, 3-30 months). All treated fractures were anterior and posterior element injuries with distraction. Three patients presented delayed onset preoperative neurological deficit following trauma. The mean operation time was 179.6 minutes (range, 92-340 minutes). The mean hemorrhage was 103.6 mL (range, unquantifiable to 480 mL). Radiological evaluations at FU showed preservation of the acceptable postoperative correction of the fractured vertebra, as there were no re-collapses of the fractured vertebrae during FU. ASD patients must be acknowledged as highly susceptible to unstable spinal fractures, even after relatively mild trauma. MISt using PPSs may be an effective treatment for spinal fractures in such patients.
1 January 2000 in Archives of orthopaedic and trauma surgery
We report herein on 15 cases of pulmonary metastases from squamous cell carcinoma of the head and neck (SCCHN) treated with modified TPF chemotherapy (docetaxel combined with nedaplatin and 5-FU). TPF chemotherapy is known as a neoajuvant chemotherapy regimen. We modified the TPF chemotherapy using nedaplatin as a substitute for cisplatin. We tried 4 courses of modified TPF chemotherapy every 3 weeks, docetaxel 60 mg/m2 on day 1; nedaplatin 75 mg/m2 on day 1 and 5-FU 1000 mg/body by continuous infusion on days 1 to 4. 11 patients received 4 courses, and the remaining of 4 patients recieved 1-3 courses because of their poor general condition. Of the 15 patients, 13 were males and 2 were females with ages ranging from 43 to 73 years (mean, 59.1 yr). Two of the primary sites were in the nasopharynx, 2 in orophanrynx, 4 in the hypopharynx, 2 in the larynx and 4 in the oral cavity. Clinically there were 7 complete responders, 4 partial responders, 2 with no change, and 2 with progressive disease. The mean overall survival was 46.5 months. TPF chemotherapy may improve the overall survival.